181 related articles for article (PubMed ID: 37749907)
1. Oncolytic virotherapies for pediatric tumors.
Gross EG; Hamo MA; Estevez-Ordonez D; Laskay NM; Atchley TJ; Johnston JM; Markert JM
Expert Opin Biol Ther; 2023; 23(10):987-1003. PubMed ID: 37749907
[TBL] [Abstract][Full Text] [Related]
2. Clinical advances in oncolytic virotherapy for pediatric brain tumors.
Ghajar-Rahimi G; Kang KD; Totsch SK; Gary S; Rocco A; Blitz S; Kachurak K; Chambers MR; Li R; Beierle EA; Bag A; Johnston JM; Markert JM; Bernstock JD; Friedman GK
Pharmacol Ther; 2022 Nov; 239():108193. PubMed ID: 35487285
[TBL] [Abstract][Full Text] [Related]
3. Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
Bernstock JD; Bag AK; Fiveash J; Kachurak K; Elsayed G; Chagoya G; Gessler F; Valdes PA; Madan-Swain A; Whitley R; Markert JM; Gillespie GY; Johnston JM; Friedman GK
Hum Gene Ther; 2020 Oct; 31(19-20):1132-1139. PubMed ID: 32657154
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H; Ino Y; Todo T
Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme.
Kazemi Shariat Panahi H; Dehhaghi M; Lam SS; Peng W; Aghbashlo M; Tabatabaei M; Guillemin GJ
Semin Cancer Biol; 2022 Nov; 86(Pt 3):1122-1142. PubMed ID: 34004331
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
7. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
9. Targeted oncolytic herpes simplex viruses for aggressive cancers.
Wong J; Lee C; Zhang K; Rennie PS; Jia W
Curr Pharm Biotechnol; 2012 Jul; 13(9):1786-94. PubMed ID: 21740360
[TBL] [Abstract][Full Text] [Related]
10. Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.
Waters AM; Johnston JM; Reddy AT; Fiveash J; Madan-Swain A; Kachurak K; Bag AK; Gillespie GY; Markert JM; Friedman GK
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):7-16. PubMed ID: 28319448
[TBL] [Abstract][Full Text] [Related]
11. Development of oncolytic virotherapy: from genetic modification to combination therapy.
Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
[TBL] [Abstract][Full Text] [Related]
12. Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S; Gao L; Yeagy B; Reid T
Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
[TBL] [Abstract][Full Text] [Related]
13. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic Virus-Driven Biotherapies from Bench to Bedside.
Duan S; Wang S; Qiao L; Yu X; Wang N; Chen L; Zhang X; Zhao X; Liu H; Wang T; Wu Y; Li N; Liu F
Small; 2023 Jun; 19(23):e2206948. PubMed ID: 36879416
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic herpes simplex virus therapy for peripheral nerve tumors.
Jeyaretna DS; Rabkin SD; Martuza RL
Neurosurg Focus; 2007 Jun; 22(6):E4. PubMed ID: 17613221
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic herpes simplex virus and immunotherapy.
Ma W; He H; Wang H
BMC Immunol; 2018 Dec; 19(1):40. PubMed ID: 30563466
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic vaccinia virus: from bedside to benchtop and back.
Thorne SH
Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical.
Tang C; Li L; Mo T; Na J; Qian Z; Fan D; Sun X; Yao M; Pan L; Huang Y; Zhong L
Clin Transl Oncol; 2022 Sep; 24(9):1682-1701. PubMed ID: 35612653
[TBL] [Abstract][Full Text] [Related]
19. Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine.
Li QX; Liu G; Zhang X
Curr Pharm Biotechnol; 2012 Jul; 13(9):1773-85. PubMed ID: 21740353
[TBL] [Abstract][Full Text] [Related]
20. Targeting pediatric cancer stem cells with oncolytic virotherapy.
Friedman GK; Cassady KA; Beierle EA; Markert JM; Gillespie GY
Pediatr Res; 2012 Apr; 71(4 Pt 2):500-10. PubMed ID: 22430386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
